What is lutetium-177 PSMA therapy?
Lutetium-177 PSMA therapy is a type of targeted internal radiotherapy for advanced prostate cancer. It uses a medicine that combines a radioactive substance, lutetium-177, with a molecule that seeks out a protein called PSMA (prostate-specific membrane antigen). The approved medicine is called lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or by its brand name, Pluvicto.
Most prostate cancer cells carry large amounts of PSMA on their surface. After the medicine is injected into a vein, it travels around the body and attaches to PSMA wherever the cancer is: in bones, lymph nodes or organs. The lutetium-177 then gives off radiation that damages and kills the cancer cells from very close range.
This kind of treatment is called radioligand therapy. It is used for men whose prostate cancer has spread and keeps growing despite hormone treatment, a stage called metastatic castration-resistant prostate cancer. A special PSMA scan is done first to check that the cancer carries enough PSMA for the treatment to work.
A brief history
The PSMA protein was identified in the 1980s and 1990s. In the early 2010s, researchers in Germany developed small molecules that bind tightly to PSMA and can carry either a substance that shows up on PET scans or a radioactive substance for treatment. Early use of lutetium-177 PSMA in Germany and Australia showed promising results. The VISION trial, published in 2021, showed that the treatment helped men live longer (Sartor et al., 2021), and it was approved in the United States and Europe in 2022.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Radionuclide (radioligand) therapy |
| Medicine | Lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617, Pluvicto) |
| Main use | Metastatic castration-resistant prostate cancer that shows PSMA on a PET scan |
| How it is given | Injection or short drip into a vein |
| Schedule | Every 6 weeks, usually up to 6 doses |
| Setting | Nuclear medicine department; usually as an outpatient |
| Main side effects | Tiredness, dry mouth, nausea, low blood counts, kidney effects |
2. How it works
Finding the cancer
| Part of the medicine | Role |
|---|---|
| PSMA-targeting molecule | Binds to PSMA on prostate cancer cells |
| Linker and chelator | Holds the radioactive metal firmly |
| Lutetium-177 | Emits beta radiation that damages cancer cells |
How the radiation works
Lutetium-177 mainly gives off beta particles, which travel up to about 2 millimetres in tissue. This short range means the radiation is concentrated on the cancer and nearby cells. It also gives off a small amount of gamma radiation, which allows scans to show where the medicine has gone.
Why a PSMA scan comes first
Before treatment, a PSMA PET scan shows whether the cancer has enough PSMA. If some areas of cancer do not take up the tracer, the treatment may not reach them, and another treatment may be better.
A related treatment
The same principle of a radioactive substance carried by a targeting molecule is used in other cancers. For example, peptide receptor radionuclide therapy uses lutetium-177 attached to a different molecule to treat neuroendocrine tumours.
Why PSMA is a good target
PSMA is found in high amounts on most prostate cancer cells and in much lower amounts on most healthy tissues. Its levels often rise as prostate cancer becomes more advanced or resistant to hormone treatment. This makes it a useful target both for finding prostate cancer on scans and for delivering treatment. A small number of healthy tissues, such as the salivary and tear glands, kidneys and parts of the bowel, also take up PSMA-targeting medicines, which explains some of the side effects.
3. Who it is for
Conditions treated
| Condition | Role of lutetium-177 PSMA therapy |
|---|---|
| Prostate adenocarcinoma | Metastatic castration-resistant disease that has PSMA on scans, usually after hormone medicines and often after chemotherapy |
Who may be suitable
| Usually suitable | Usually not suitable |
|---|---|
| Cancer growing despite hormone therapy | Areas of cancer with little or no PSMA on the scan |
| Cancer shows PSMA uptake on PET | Very low blood counts |
| Already treated with a newer hormone medicine | Poor kidney function |
| Reasonable general health | Very poor general health |
Timing of treatment
In the VISION trial, men had already received at least one newer hormone medicine and one or two courses of taxane chemotherapy (Sartor et al., 2021). The PSMAfore trial studied men who had not yet had chemotherapy, after a newer hormone medicine had stopped working (Morris et al., 2024). Approval depends on the country, so your team will explain where it fits for you.
4. Before treatment
| Step | Why it is done |
|---|---|
| PSMA PET-CT scan | Confirms the cancer carries PSMA |
| Sometimes an FDG PET scan | Looks for areas that do not show PSMA |
| Blood counts | The bone marrow must be able to cope |
| Kidney function | The medicine is cleared by the kidneys |
| Discussion of other options | Including chemotherapy, other hormone medicines and radium-223 |
| Radiation safety briefing | Precautions for home |
Hydration
You are usually asked to drink plenty of fluids before and after each treatment. This helps the kidneys clear any medicine that has not attached to the cancer and reduces the dose to the bladder.
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Arrival | At the nuclear medicine department |
| 2. Blood tests | Before each cycle |
| 3. Cannula | A small tube is placed in a vein |
| 4. Anti-sickness medicine | Sometimes given beforehand |
| 5. Infusion | Given over about 30 minutes or as a slow injection |
| 6. Monitoring | A few hours in the department while radiation levels fall |
| 7. Scan | Sometimes a scan a day or so later shows where the medicine went |
| 8. Home | Usually the same day, with safety instructions |
| 9. Repeat | Every 6 weeks, up to 6 doses |
Radiation safety at home
| Precaution | Typical duration |
|---|---|
| Limit close contact with others, especially children and pregnant women | A few days after each dose |
| Sleep in a separate bed | A few days |
| Sit to pass urine and flush twice | About a week |
| Wash hands thoroughly | About a week |
| Avoid sexual activity, or use condoms | As advised by your team |
| Drink plenty of fluids | Several days |
Rules vary by country and hospital, so always follow your own team’s instructions.
What a treatment day feels like
Most men find the treatment day itself straightforward. The infusion is painless, and you can usually read, use a phone or listen to music while you wait. Bring snacks, a water bottle and something to pass the time. Some hospitals ask you to stay in a separate waiting area while radiation levels fall, so it can be helpful to arrange for someone to collect you rather than travel on busy public transport.
Fertility and contraception
The treatment can affect sperm production and could harm a baby conceived during or shortly after treatment. Your team will advise on contraception and on how long to wait after the last dose. Sperm banking can be discussed beforehand if relevant.
6. Side effects and risks
| Side effect | What to expect |
|---|---|
| Tiredness | Common |
| Dry mouth | Common, because the salivary glands take up the medicine |
| Nausea and loss of appetite | Usually mild |
| Low blood counts | Anaemia, low platelets or low white cells |
| Constipation or diarrhoea | Sometimes |
| Kidney changes | Monitored with blood tests |
| Dry eyes | Sometimes |
How serious are the side effects?
In the VISION trial, severe side effects were more common with lutetium-177 PSMA plus standard care than with standard care alone (53% versus 38%), but quality of life was not made worse (Sartor et al., 2021). In the TheraP trial, severe side effects were less common with lutetium-177 PSMA than with cabazitaxel chemotherapy (33% versus 53%) (Hofman et al., 2021).
Dry mouth
The salivary glands pick up some of the medicine. Dry mouth is usually mild and may improve, but it can persist. Sipping water, sugar-free gum and saliva substitutes help. Good dental care is important.
7. Results and outlook
| Study | Main finding |
|---|---|
| VISION trial, 831 men | Adding lutetium-177 PSMA to standard care improved median survival from 11.3 to 15.3 months and delayed scan progression from 3.4 to 8.7 months (Sartor et al., 2021) |
| TheraP trial, 200 men | PSA fell by at least half in 66% with lutetium-177 PSMA versus 37% with cabazitaxel (Hofman et al., 2021) |
| PSMAfore trial, 468 men | Before chemotherapy, lutetium-177 PSMA delayed scan progression compared with switching to another hormone medicine (Morris et al., 2024) |
What the results mean
Lutetium-177 PSMA therapy does not cure advanced prostate cancer, but it can help men live longer, slow the cancer and relieve symptoms such as bone pain. It works best when the PSMA scan shows strong uptake throughout the cancer.
Checking the response
Your team will check PSA blood levels, symptoms and scans during and after treatment. If the cancer responds very well, treatment may be paused, and it may be possible to restart later.
8. Recovery and aftercare
| Tip | Why |
|---|---|
| Drink plenty of fluids | Protects the kidneys and bladder |
| Follow radiation precautions | Protects others |
| Look after your mouth | Reduces dry mouth problems |
| Report fever, bleeding or bruising | May indicate low blood counts |
| Rest but keep active | Helps fatigue |
| Continue hormone therapy | Usually continued throughout |
Follow-up
You will have blood tests before each cycle and regular reviews. PSMA scans may be repeated during or after treatment to assess the response.
Bone pain and other symptoms
Some men notice a short-lived increase in bone pain in the days after a dose. This usually settles and can be eased with simple painkillers. Over the course of treatment, many men find that bone pain improves as the cancer responds. Tell your team about any new back pain, weakness or numbness in the legs, as this needs urgent assessment.
Living with advanced prostate cancer
Advanced prostate cancer affects many parts of life. Specialist nurses, palliative care teams, counsellors and support groups can help with symptoms, emotions and planning. Palliative care can be helpful at any stage, not only at the end of life.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Androgen deprivation therapy | Continued alongside most treatments for advanced prostate cancer |
| Radium-223 therapy | Cancer mainly in the bones, without spread to organs |
| PARP inhibitors | Cancers with BRCA or similar gene changes |
| Chemotherapy (docetaxel or cabazitaxel) | Fit men with advancing cancer |
| Palliative radiotherapy | To treat a single painful area |
| Newer hormone medicines | Such as abiraterone or enzalutamide |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Will I be radioactive? | Yes, for a few days; follow your team’s safety advice |
| Can I be around my grandchildren? | Limit close contact for a few days after each dose |
| Does it cause hair loss? | Hair loss is uncommon |
| How long does each treatment take? | The infusion takes minutes; the visit takes several hours |
| Can I travel? | Ask for a letter, as airport detectors may pick up radiation |
| Is it the same as radium-223? | No; radium-223 targets bone, while lutetium-177 PSMA targets PSMA anywhere in the body |
| Can I drive home? | Usually yes, although the team may advise on keeping distance from passengers |
| Can I have it more than 6 times? | Sometimes, in selected cases after a break; ask your team |
| Do I need to stay in hospital? | Usually not, though some hospitals keep patients for a short time |
| Will my PSA fall? | In many men it does, which is a good sign |
11. Questions to ask your care team
- Does my PSMA scan show that I am suitable?
- Where does this treatment fit among my other options?
- What side effects should I expect?
- What precautions do I need to take at home?
- How will we know if it is working?
- What happens if my blood counts fall?
Resources
- Hofman, M.S. et al. (2021) ‘[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial’, The Lancet, 397(10276), pp. 797-804.
- Morris, M.J. et al. (2024) ‘177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial’, The Lancet, 404(10459), pp. 1227-1239.
- Sartor, O. et al. (2021) ‘Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer’, New England Journal of Medicine, 385(12), pp. 1091-1103.
- National Cancer Institute (2026) Lutetium Lu 177 Vipivotide Tetraxetan. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/lutetium-lu-177-vipivotide-tetraxetan (Accessed: October 2026).
- National Cancer Institute (2026) Prostate Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.